Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer Academic Article uri icon

Overview

MeSH Major

  • Abiraterone Acetate
  • Prednisone
  • Prostatic Neoplasms, Castration-Resistant

abstract

  • Abiraterone acetate demonstrated clinical benefit and was well tolerated in elderly and younger men with chemotherapy naïve, metastatic castration resistant prostate cancer. Thus, findings support it as a treatment option for elderly patients who may not tolerate other therapies with greater toxicity.

publication date

  • November 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5129174

Digital Object Identifier (DOI)

  • 10.1016/j.juro.2015.07.004

PubMed ID

  • 26151676

Additional Document Info

start page

  • 1277

end page

  • 84

volume

  • 194

number

  • 5